Gary Steven, MD
Allergy · Greenfield, WINPI 1972530699
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by AstraZeneca at 30.4% of the total. Reporting peaked in 2019 at $55,431 and has fallen 74.0% since, to $14,396 in 2025.
Across 835 payments — averaging $183.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$46K
- GSK$29K
- Sanofi$19K
- Novartis$19K
- Optinose US, Inc.$14K
- Regeneron Healthcare Solutions, Inc.$12K
- plus $14K from 32 others
Across 930 payments — averaging $5387.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.7M
- Teva Pharmaceuticals USA, Inc.$684K
- Novartis$353K
- Cipla USA Inc.$272K
- Amphastar Pharmaceuticals, Inc.$268K
- Regeneron$249K
- plus $1.5M from 13 others
What the payments were for
- Consulting fees$29,37119%
- Speaking & faculty fees$87,74057%
- Travel & lodging$10,6727%
- Food & beverage$24,80816%
- Education$2740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 194 | $46,440 |
| GSK | 133 | $28,942 |
| Sanofi | 69 | $19,159 |
| Novartis | 37 | $18,567 |
| Optinose US, Inc. | 54 | $14,007 |
| Regeneron Healthcare Solutions, Inc. | 45 | $12,186 |
| Grifols USA, LLC | 20 | $3,238 |
| Alk-abello, Inc | 46 | $2,089 |
| Genentech USA, Inc. | 15 | $1,950 |
| Teva Pharmaceuticals USA, Inc. | 47 | $1,389 |
| Covis Pharma GmbH | 29 | $580 |
| Amgen | 22 | $546 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $544 |
| Pfizer | 20 | $479 |
| Boehringer Ingelheim | 19 | $437 |
| Shionogi Inc | 6 | $427 |
| Eli Lilly | 1 | $288 |
| Mylan Specialty L.p. | 12 | $224 |
| CSL Behring | 5 | $162 |
| Verona Pharma, Inc. | 2 | $151 |
| Kaleo, Inc. | 8 | $136 |
| Genentech, Inc. | 1 | $112 |
| Blueprint Medicines Corporation | 1 | $109 |
| Kyowa Kirin, Inc. | 1 | $97 |
| Hospira, Inc. | 4 | $86 |
| Circassia Inc. | 3 | $80 |
| Sanofi-aventis U.S. LLC | 2 | $75 |
| LEO Pharma Inc. | 3 | $66 |
| Octapharma USA, Inc. | 2 | $52 |
| Biocryst US Sales Co., LLC | 3 | $50 |
| Pharming Healthcare, Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $37 |
| USWM, LLC | 2 | $35 |
| Merck | 2 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Greer Laboratories, Inc. | 1 | $17 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$30,477
- DUPIXENT$28,704
- NUCALA$19,230
- Xhance$13,186
- XOLAIR$11,638
- FASENRA$8,294
- TRELEGY ELLIPTA$7,300
- Xembify$2,808
- BREZTRI$1,960
- BREZTRI AEROSPHERE$900
- Odactra$745
- TEZSPIRE$693
- Ragwitek$350
- Grastek$350
- AirDuo Digihaler$343
- GILENYA$278
- Dust mite (D. farinae)$163
- Ohtuvayre$125
- Prolastin-C$125
- CINQAIR$122
How this compares
Too few allergy providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 34 | $158,318 |
| Dupixent PenDupilumab | 22 | $113,676 |
| XolairOmalizumab | 33 | $102,120 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $78,584 |
| Arnuity ElliptaFluticasone Furoate | 124 | $49,385 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $45,815 |
| NucalaMepolizumab | 12 | $41,889 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $28,148 |
| Spiriva HandihalerTiotropium Bromide | 27 | $26,315 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $26,169 |
| SymbicortBudesonide/Formoterol Fumarate | 74 | $25,929 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $19,962 |
| Qvar RedihalerBeclomethasone Dipropionate | 47 | $18,832 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $17,944 |
| Spiriva RespimatTiotropium Bromide | 21 | $15,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Nucala, Anoro Ellipta, Breo Ellipta | $28,942 | $224,175278 claims |
| Genentech, Inc.Xolair | $112 | $102,12033 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $46,440 | $78,465137 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat | $437 | $33,63843 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $1,389 | $18,83247 claims |
| MerckDulera, Asmanex | $23 | $9,47432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Wisconsinon file to place this against a meaningful peer group, so we don't.
Other allergy in Greenfield
- David EdmondsonWausau$207K
- Mark MossMadison$16K
- Ravi ViswanathanMadison$4K
- Courtney GaberinoMadison$1K
- Helen SandersonMadison$762
- Pedro BandaMilwaukee$149
- Martin LobelMilwaukee$123
- Ivana SurjancevMadison$34
- Mark BiagtanMadison$19
- Michael GanzRacine$11
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.